PF-Atlas › Clinical Trials › NCT04318704

Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough

Ifenprodil · ANZCTR · Phase 2

Registry ID
NCT04318704
Phase
Phase 2
Status
Completed
Drug / intervention
Ifenprodil
Mechanism
ANZCTR
Sponsor
Algernon Pharmaceuticals
Start
2020-07-29
Enrollment
20
Locations
6

About this trial

NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF). In addition, NP-120 significantly reduced both cough frequency and onset in a guinea pig tussive model. The purpose of this proof-of-concept trial is to determine the efficacy of NP-120 in the treatment of IPF and its associated cough.

View NCT04318704 on ClinicalTrials.gov →

Explore related

All Ifenprodil trialsANZCTR mechanismAll IPF trials

Related trials

Inhaled mannitol — NCT00669331PTI-808 — NCT03251092BI 1819479 — NCT06335303AP01 — NCT06951217CMS — NCT03093974AZLI 75 mg three times a day — NCT00112359
Medical disclaimer. This page summarizes public trial data for NCT04318704 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.